Longevity & AgingPfizer-BioNTech Pivotal Trial Confirms BNT162b2 Safety and Efficacy Across Ages
This is the pivotal clinical trial behind the Pfizer-BioNTech COVID-19 vaccine (BNT162b2). Spanning Phases 1 through 3, it enrolled healthy individuals aged 12 and older to evaluate the safety, tolerability, immunogenicity, and efficacy of three RNA vaccine candidates. The selected candidate, BNT162b2 at 30 µg given in two doses 21 days apart, was assessed across multiple age groups. The trial expanded over time to include booster dose evaluations, lower-dose regimens, and variant-specific vaccine candidates including one targeting the South African SARS-CoV-2 variant. Placebo recipients were later offered active vaccination. This study formed the regulatory foundation for Emergency Use Authorization and subsequent full approval of the Pfizer-BioNTech vaccine globally.
